← All trials
NCT06138210
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2024
- Primary completion
- Aug 30, 2025
- Completion date
- Aug 30, 2025
- First posted
- Nov 18, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 29
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.Collaborator
- Capital Medical UniversityOverall official - principal investigator
- Capital Medical UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.